You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
AAAPT Technology for Improving Chemotherapy
SBC: SCI-ENGI-MEDCO SOLUTIONS, INC Topic: NCIDESCRIPTION provided by applicant Dysregulation of apoptosis pathways and loss of Human Beta Defensin hBD are the common tactics adapted by cancer cells to circumvent the effects of chemotherapy Consequently high dose of chemotherapy is required to obtain a clinically relevant therapeutic index which in turn compromises safety and develops resistance to therapy The problem is acute p ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Experimental Design Software for Translational Gastrointestinal Microbiome Studie
SBC: WILLIAM D SHANNON CONSULTING LLC Topic: 300DESCRIPTION provided by applicant Design of experiments and test of hypotheses need to be available to research teams to develop and validate taxonomic metagenomic biomarkers in gastrointestinal tract GIT diseases The translational research team needs to design an experiment to test a hypothesis e g microbiota in Crohnandapos s disease is different than in normal controls calculat ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Rapid STEMI Fibrinolysis for Underserved Populations
SBC: Pulse Therapeutics, Inc. Topic: NIMHDDESCRIPTION provided by applicant Coronary heart disease CHD accounts for every of deaths in the United States US with acute incidences estimated at M annually Of these up to are classified as ST elevation myocardial infarction STEMI in which a clot blocks a coronary artery leading to a change in the ECG ST wave Because the heart muscle rapidly dies time to re ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
MIST System for Simultaneous Parallel Intracellular Delivery & Transfection
SBC: OPENCELL TECHNOLOGIES, INC. Topic: 400DESCRIPTION provided by applicant Alternative nanomaterial and gene transfer solutions are needed to access the potential held in intracellular imaging biopharmaceuticals gene therapy and stem cell research Delivery of small and macromolecules including nucleic acids drug molecules imaging agents peptides antibodies and enzymes into cells is criti ...
SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health -
Anti-virulence FimH inhibitors for the treatment and prevention of UTIs
SBC: FIMBRION THERAPEUTICS INC Topic: NIAIDDESCRIPTION provided by applicant Over million women suffer from urinary tract infections UTI annually in the U S and approximately of these patients suffer from multiple recurrences UTI is unique in its high prevalence of chronic recurrent infections which has caused a tremendous need for long term conventional prophylactic therapy This is leading to increased antimicrobial res ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Direct RT-PCR detection of RNA pathogens in crude samples
SBC: DNA POLYMERASE TECHNOLOGY, INC. Topic: 200DESCRIPTION provided by applicant The objective of this application is to introduce a novel simplified low cost technology to address the broad need of detecting RNA pathogens directly in crude samples such as blood Traditional RT PCR requires purifying the RNA which increases the cost time and risk of cross contamination We intend to reduce or eliminate the purification step by producin ...
SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health -
Expanding small molecule functional metagenomics through shuttle BAC expression i
SBC: INTACT GENOMICS INC Topic: NIAIDDESCRIPTION provided by applicant Hospital acquired microbial infections are the fourth largest killer in America taking lives and adding $ B to hospital costs The emergence of drug resistant microbes has further amplified public health concern Fungi are prolific producers of anti microbial secondary metabolites SM and since the turn of the century have provided of bioactive m ...
SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health -
A FLUOROMETRIC SENSOR FOR Cr(VI)
SBC: MARKTEK INC Topic: N/AHexavalent chromium, Cr(VI), in the usual form of oxo species, is used in manyindustrial processes and products. As a consequence, Cr(VI)= containingcompounds are often found in wastewater and contaminated sites. Since Cr(VI) isconsidered highly toxic and carcinogenic, it is extremely important to have areliable, easy-to-use, sensitive monitor for determining Cr(VI) concentrationsin process, on ...
SBIR Phase I 1995 Environmental Protection Agency -
Glycoengineered baculoviruses for the production of more efficacious influenza va
SBC: Glycobac, LLC Topic: NIAIDDESCRIPTION (provided by applicant): Vaccination significantly reduces morbidity and mortality caused by annual influenza epidemics. Traditionally, influenza vaccines have been manufactured using adapted influenza virus grown in eggs. However, this methodsuffers from inherent disadvantages such as slow production and allergenic egg proteins in the final product. To avoid these drawbacks, new vacci ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Development of TAK1 Compounds for Neonatal Onset Multisystem Inflammatory Disease
SBC: CONFLUENCE LIFE SCIENCES, INC. Topic: NIAMSDESCRIPTION (provided by applicant): Cryopyrin-associated periodic syndromes (CAPS) are a family of rare autoinflammatory diseases of which neonatal-onset multisystem inflammatory disease (NOMID) is the most severe phenotype. NOMID is characterized by NLRP3 activating mutations resulting in excessive interleukin- 1?IL-1?and IL-18 production associated with recurrent fever, rash, skeletal lesions, ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health